Literature DB >> 30008865

Influence of YKL-40 gene RNA interference on the biological behaviors of endometrial cancer HEC-1A cells.

Lili Li1, Jiangtao Fan1, Dahai Li1, Yan Liu1, Poonam Shrestha1, Chunyan Zhong1, Xiuhong Xia1, Xiaobing Huang1.   

Abstract

The present study aimed to investigate the effects of chitinase-3-like protein 1 (YKL-40) gene RNA interference on the biological behaviors and enhanced chemosensitivity of endometrial cancer (EC) HEC-1A cells. YKL-40 small interfering (si)RNA was transduced into EC HEC-1A cells using a lentivirus. The experiment was divided into three groups: The experimental group was transfected with YKL-40 siRNA (si-YKL-40); the mock-treatment group was transfected with transfection reagent only; and the blank control group was left untreated. A reverse transcription-quantitative polymerase chain reaction was performed to investigate the mRNA expression levels of YKL-40. The biological behaviors, including cell proliferation, migration, invasion and apoptosis, were detected by MTT and Transwell assays, and flow cytometry (FCM) analysis, respectively. The results of the present study demonstrated that the mRNA expression levels of YKL-40 were downregulated within HEC-1A cells upon transfection with si-YKL-40 (P<0.05). The proliferative, migratory and invasive abilities of HEC-1A cells were inhibited by si-YKL-40 (P<0.05). The mRNA expression levels of YKL-40 were upregulated within HEC-1A cells following treatment with cisplatin (P<0.05). FCM analysis revealed that the average cellular apoptosis rate increased following the inhibition of YKL-40 gene expression via siRNA (P<0.05). Therefore, the YKL-40 gene may be associated with the proliferative, migratory, invasive and anti-apoptotic ability of HEC-1A cells. YKL-40 downregulation may enhance the sensitivity of human EC HEC-1A cells to chemotherapy.

Entities:  

Keywords:  EC; YKL-40; biological behaviors; chemotherapy; cisplatin; siRNA

Year:  2018        PMID: 30008865      PMCID: PMC6036507          DOI: 10.3892/ol.2018.8814

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  31 in total

1.  YKL-40 is differentially expressed in human embryonic stem cells and in cell progeny of the three germ layers.

Authors:  Christian B Brøchner; Julia S Johansen; Lars A Larsen; Mads Bak; Hanne B Mikkelsen; Anne Grete Byskov; Claus Yding Andersen; Kjeld Møllgård
Journal:  J Histochem Cytochem       Date:  2011-12-01       Impact factor: 2.479

2.  CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells.

Authors:  Bo Mi Ku; Yeon Kyung Lee; Jinhyun Ryu; Joo Yeon Jeong; Jungil Choi; Keyoung Mi Eun; Hye Young Shin; Dong Gyu Kim; Eun Mi Hwang; Jae Cheal Yoo; Jae-Yong Park; Gu Seob Roh; Hyun Joon Kim; Gyeong Jae Cho; Wan Sung Choi; Sun Ha Paek; Sang Soo Kang
Journal:  Int J Cancer       Date:  2011-03-15       Impact factor: 7.396

3.  Serum and tissue level of YKL-40 in endometrial cancer.

Authors:  J T Fan; M J Li; P Shen; H Xu; D H Li; H Q Yan
Journal:  Eur J Gynaecol Oncol       Date:  2014       Impact factor: 0.196

4.  Chitosan leads to downregulation of YKL-40 and inflammasome activation in human macrophages.

Authors:  Steinunn Gudmundsdottir; Ramona Lieder; Olafur E Sigurjonsson; Petur H Petersen
Journal:  J Biomed Mater Res A       Date:  2015-02-27       Impact factor: 4.396

5.  Chitinase 3-like-1 expression in colonic epithelial cells as a potentially novel marker for colitis-associated neoplasia.

Authors:  Chun-Chuan Chen; Joel Pekow; Victoria Llado; Manasa Kanneganti; Cindy W Lau; Atsushi Mizoguchi; Mari Mino-Kenudson; Marc Bissonnette; Emiko Mizoguchi
Journal:  Am J Pathol       Date:  2011-07-16       Impact factor: 4.307

6.  Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma.

Authors:  Anne K Mylin; Niels Abildgaard; Julia S Johansen; Lene Heickendorff; Svend Kreiner; Anders Waage; Ingemar Turesson; Peter Gimsing
Journal:  Leuk Lymphoma       Date:  2015-02-11

7.  Pathology of Endometrial Carcinoma.

Authors:  Sigurd F Lax
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

8.  YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation.

Authors:  Anne Roslind; Julia S Johansen
Journal:  Methods Mol Biol       Date:  2009

9.  Estrogen promotes fat mass and obesity-associated protein nuclear localization and enhances endometrial cancer cell proliferation via the mTOR signaling pathway.

Authors:  Yaping Zhu; Jiaqi Shen; Liyan Gao; Youji Feng
Journal:  Oncol Rep       Date:  2016-02-05       Impact factor: 3.906

10.  YKL-40 regulated epithelial-mesenchymal transition and migration/invasion enhancement in non-small cell lung cancer.

Authors:  Malvin Jefri; Yi-Ning Huang; Wen-Chien Huang; Chun-San Tai; Wen-Liang Chen
Journal:  BMC Cancer       Date:  2015-08-15       Impact factor: 4.430

View more
  1 in total

1.  Exosomal lncRNA NEAT1 from cancer-associated fibroblasts facilitates endometrial cancer progression via miR-26a/b-5p-mediated STAT3/YKL-40 signaling pathway.

Authors:  Jiang-Tao Fan; Zhao-Yu Zhou; Yan-Lu Luo; Qin Luo; Si-Bang Chen; Jin-Che Zhao; Qiao-Ru Chen
Journal:  Neoplasia       Date:  2021-06-18       Impact factor: 5.715

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.